This was further exemplified in the longitudinal late-stage administration studies, which showed that AAV-PKP2 could revert multiple histopathological cardiac abnormalities (reduction in cardiac fibrosis, fat deposition, inflammation and cytokine production) and physiological cardiac abnormalities (improvements in left and right ventricular dimensions and function, alleviation of cardiac arrhythmias) in PKP2 Hom mice. Here, PKP2 is linked to chronic obstructive pulmonary disease.